- Home
- JEF vs QGEN Comparison
JEF vs QGEN Comparison
Compare JEF & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JEF | QGEN |
|---|---|---|
| Founded | 1968 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.2B |
| IPO Year | 2014 | 1998 |
Fundamental Metrics
Financial Performance| Metric | JEF | QGEN |
|---|---|---|
| Price | $52.43 | $40.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $61.40 | $45.76 |
| AVG Volume (30 Days) | ★ 2.3M | 2.2M |
| Earning Date | 03-25-2026 | 05-06-2026 |
| Dividend Yield | 3.37% | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $10,823,677,000.00 | N/A |
| Revenue This Year | $13.23 | $8.18 |
| Revenue Next Year | $10.25 | $5.71 |
| P/E Ratio | $75.17 | ★ $24.01 |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $35.53 | $32.53 |
| 52 Week High | $71.04 | $57.82 |
Technical Indicators
Market Signals| Indicator | JEF | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 65.55 |
| Support Level | $50.67 | $38.80 |
| Resistance Level | $54.11 | $42.33 |
| Average True Range (ATR) | 2.26 | 0.73 |
| MACD | -1.32 | 0.26 |
| Stochastic Oscillator | 34.62 | 97.99 |
Price Performance
Historical ComparisonAbout JEF Jefferies Financial Group Inc.
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).